US Drug Recall Register
Class I · High risk Terminated Initiated Aug 3, 2017 (9 years ago)

Lorazepam Oral Concentrate

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.

What was recalled

Lorazepam Oral Concentrate, USP, 2 mg/mL, 30 mL bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Branchburg, NJ 08876. Distributed by: Amneal Pharmaceuticals, Glasgow, KY 42141. NDC 65162-687-84

Recalling firm
Amneal Pharmaceuticals of New York, LLC
NDC code
65162-687-84
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0120-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Lorazepam recalls

See all
Class II · Moderate risk Ongoing

Lorazepam Injection

Reason Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class II · Moderate risk Ongoing

Lorazepam 0.5 mg per 0.25 mL Oral Syringe

Reason Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.

Safecor Health, LLC D-0253-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0228-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0227-2025
Class II · Moderate risk Ongoing

Lorazepam Tablets

Reason Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories D-0226-2025